Liver-protecting effects of omega-3 fish oil lipid emulsion in liver transplantation

Table 1 Clinical data of the enrolled patients

	PN group	PUFA group
Sex (M/F)	23/10	22/11
Age, yr	48.62 ± 14.61	51.52 ± 12.41
Clinical diagnosis
Hepatic cell carcinoma	13	14
Post- hepatitis B liver cirrhosis	17	18
Alcoholic liver cirrhosis	1	0
Primary biliary liver cirrhosis	1	1
Congenital polycystic liver	1	0
Child-Pugh classification (A/B/C)	14/10/9	13/10/10
Warm ischemic time (min)	3.91 ± 1.16	4.15 ± 1.32
Cold ischemic time (min)	524.28 ± 132.83	506.56 ± 151.26
Operation period (min)	651.27 ± 181.42	626.39 ± 192.86
Anhepatic phase (min)	119.81 ± 82.35	142.15 ± 58.75
Immunosuppressive therapy	22/11/0	21/11/1
(FK506 + P/CSA + P/CSA + P + MMF)

PN: Parenteral nutrition; PUFA: Polyunsaturated fatty acid; P: Prednisone; CSA: Ciclosporin A; MMF: Mycophenolate mofetil; FK506: Tacrolimus.